Literature DB >> 11082509

Regeneration and tolerance factor's potential role in T-cell activation and apoptosis.

J S Boomer1, G W Lee, T S Givens, A Gilman-Sachs, K D Beaman.   

Abstract

Regeneration and tolerance factor (RTF) is a novel membrane protein that has a diverse expression pattern and immunoregulatory properties. RTF is expressed in vivo on the surface of individuals with B cell chronic lymphocytic leukemia and on activated T lymphocytes of HIV infected individuals as determined by their coexpression with CD38 and HLA-DR. The unique expression patterns of this protein in vivo lead us to investigate its expression in vitro. The activation of human PBMCs through the TCR, using anti-CD3 antibody and PMA, upregulated cell surface expression of RTF from 2. 3% to 91.2% (mean channel fluorescence [MCF] increased threefold). The activation of Jurkat T cells through the TCR upregulated surface expression of RTF from 8.3% (MCF-1.3) to 58.7% (MCF-13.1). The Jurkat T-cell line was used as a model system to explore RTF's role in cellular activation. Using the Jurkat T-cell model, we found anti-RTF antibody induces apoptosis. The addition of anti-RTF antibody increased annexin V binding by threefold compared with the IgG1 kappa isotype control antibody (p < 0.00002) and activated caspase 3. These data indicate that RTF is expressed during T-cell activation and may be associated with apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082509     DOI: 10.1016/s0198-8859(00)00163-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Expression of a novel protein by regenerating hepatocytes and peripheral blood lymphocytes.

Authors:  A Chedid; C C Sung; M R Lepe; S A Ahmed; S A Iftikhar; A Feller; K D Beaman
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

3.  Regeneration and tolerance factor prevents bystander T-cell death associated with human immunodeficiency virus infection.

Authors:  Richard A Derks; Kenneth D Beaman
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

4.  Regulation of apoptosis and innate immune stimuli in inflammation-induced preterm labor.

Authors:  Mukesh K Jaiswal; Varkha Agrawal; Timothy Mallers; Alice Gilman-Sachs; Emmet Hirsch; Kenneth D Beaman
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

5.  Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Safaa Ibrahim; Sahithi Pamarthy; Mukesh K Jaiswal; Alice Gilman Sachs; Kenneth D Beaman
Journal:  Oncotarget       Date:  2015-02-28

6.  T CD3+CD8+ lymphocytes are more susceptible for apoptosis in the first trimester of normal human pregnancy.

Authors:  Dorota Darmochwal-Kolarz; Ewelina Sobczak; Piotr Pozarowski; Bogdan Kolarz; Jacek Rolinski; Jan Oleszczuk
Journal:  J Immunol Res       Date:  2014-07-20       Impact factor: 4.818

7.  Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells.

Authors:  Foroogh Nejatollahi; Payam Bayat; Bahareh Moazen
Journal:  F1000Res       Date:  2017-02-17

8.  In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Safaa A Ibrahim; Valerie E Riehl; Sylvia Schneiderman; Mahmood Bilal; Alexandria N Young; Shayna Levine; Sara Fleetwood; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2020-09-10       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.